Effect of L-dopa in Young Patients with Hypertension

Abstract

The effects of L-dopa on blood pressure, heart rate, plasma renin activity, norepinephrine, epinephrine and prolactin were studied in a randomized single-blind trial in 36 patients with essential hypertension. In response to L-dopa, 250 mg administered orally, the blood pressure decreased significantly as compared with the results of placebo treatment. The heart rate and plasma norepinephrine and epinephrine were unchanged. The plasma renin activity and prolactin decreased as a result of L-dopa administration. The administration of a peripheral DA₂ dopamine receptor blocker, domperidone (20 mg, orally) prevented the L-dopa-induced reduction in plasma prolactin but failed to block the fall in blood pressure and plasma renin activity. These results suggest that the blood pressure-lowering effect of L-dopa may be mediated through multiple sites involving D₁ dopamine receptors, the central nervous system, and the renin-angiotensin system.

Get full access to this article

View all access options for this article.

References

Goldberg LI : Dopamine receptors and hypertension. Physiologic and pharmacologic implications . Am J Med 77:37-44, 1984.

Carey RM , Stote RM , Dubb JW , et al: Selective peripheral dopamine-1 receptor stimulation with fenoldopam in human essential hypertension. J Clin Invest 74:2198-2207, 1984.

Cacero I. , LeFevre-Borg F, Gomen R: Blood pressure lowering effects of N,N-di-n-propyldopamine in rats: Evidence for stimulation of peripheral dopamine receptors leading to inhibition of sympatheric vascular tone. J Pharmacol Exp Ther 218:515-524, 1981.

Tjandramaga TB , Anton AH , Goldberg LI : Preliminary investigation of levodopa as adjunctive therapy for hypertension . In: Hypertension: Mechanism and Management, ed. by Onesti G , Kim KE , Moyer JH. New York, Grune & Stratton, 1973, pp 421-427.

Saito I. , Takeshita E. , Saruta T. , et al: Effect of a calcium entry blocker on blood pressure, plasma renin activity, aldosterone and catecholamines in normotensive subjects. Clin Endocrinol 24:565-570, 1986.

Saito I. , Takeshita E. , Saruta T. , et al: Plasma prolactin, renin and catecholamines in young normotensive and borderline hypertensive subjects. J Hypertens 2:61-64, 1984.

Judy WV , Watanabe AM , Henry DP : Effect of L-dopa on sympathetic nerve activity and blood pressure in the spontaneously hypertensive rat. Circ Res 43:24-28, 1978.

Harvey JN , Worth DP , Lee MR : Studies with fenoldopam, a dopamine receptor DA, agonist, in essential hypertension . Br J Clin Pharmacal 21:53-61, 1986.

Murphy MB , McCoy CE , Weber RR , et al: Augmentation of renal blood flow and sodium excretion in hypertensive patients during blood pressure reduction by intravenous administration of the dopamine, agonist fenoldopam. Circulation 76:1312-1318, 1987.

10.

Cuche J. , Prinseau J. , Selz F. , et al: Oral load of tyrosine or 1-dopa and plasma levels of free and sulfoconjugated catecholamines in healthy men. Hypertension 7:81-89, 1985.

11.

Carey RM , VanLoon GR , Baines AD , et al: Suppression of basal and stimulated noradrenergic activities by the dopamine agonist bromocriptine in man. J Clin Endocrinol Metab 56:595-602, 1983.

12.

Mannelli M. , Delitala G. , DeFeo ML , et al: Effects of different dopaminergic antagonists on bromocriptine-induced inhibition of norepinephrine release . J Clin Endocrinol Metab 59:74-78, 1984.

13.

Barbieri C. , Caldara R. , Ferrari C. , et al: Inhibition of the renin-angiotensin-aldosterone system by L-dopa with and without inhibition of extracerebral dopa decarboxylase in man. Clin Sci 61:187-190, 1981.

14.

Lightman SL : Studies of the responses of plasma renin activity and aldosterone and cortisol levels to dopaminergic and opiate stimuli in man. Clin Endocrinol 15:45-52, 1981.

15.

Worth DP , Harvey JN , Brown J. , et al:-L- glutamyl-L-dopa is a dopamine pro-drug, relatively specific for the kidney in normal subjects. Clin Sci 69:207-214, 1985.